Drug Profile

BRZ 101

Alternative Names: BRZ-101

Latest Information Update: 27 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GenEdit
Developer BreezeBio
Class Antihyperglycaemics; RNA
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders; Type 1 diabetes mellitus

Most Recent Events

25 Feb 2026 Preclinical trials in Autoimmune disorders in USA (unspecified route)
25 Feb 2026 Preclinical trials in Type 1 diabetes mellitus in USA (unspecified route)
25 Feb 2026 Pharmacodynamics and adverse events data from preclinical studies in Autoimmune disorders and Type 1 diabetes mellitus released by GenEdit

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com